VEGFA alternative splicing in endometrial cancer was regulated by RBM10, the expression of which was controlled by histone acetylation and DNA methylation.
We also discuss the possible relationship between metformin and MK in the context of EC, the most common gynecological cancer worldwide, which incidence is rising rapidly, in parallel with the increase in obesity, T2DM and insulin resistance.
The role of miR-27a-5p in EC migration and invasion was further investigated via transfection with miR-27a-5p mimics or inhibitor in Ishikawa and HEC-1A EC cell lines.
We further identified that silencing of JPT1 abundance does not alter cellular response to metformin or basal cell proliferation, but that JPT1 abundance does decrease in response to metformin treatment in RL95-2 and ACI-181 EC cell lines.
We think that it would be useful to determine the diagnosis, prediction of prognosis and identifying therapeutic targets of the highlighted proteins of our study that are K2C8, UAP56, GRP78 and CALR in endometrial cancer.
All in all, our research was the first endeavor to study the underlying mechanism of CHL1-AS1 in EC and confirmed that CHL1-AS1 regulated EC progression via targeting the miR-6076/CHL1 axis, offering new insight into treating EC.
The aim of the study was to determine the changes in SEMA5A expression in endometrial cancer compared to normal endometrium and to indicate the potential use of SEMA5A as a molecular marker.
Though metastasis-associated protein 1 (MTA1) is widely overexpressed in human cancers and is associated with advanced clinicopathological characteristics and survival in related diseases, the association between MTA1 and endometrial cancer (EC) is little known and needs to be studied.
Co-expression analysis showed lnc-CETP-3 was highly correlated with CHOP and HERPUD1, suggesting it might participate in ER stress pathway-related EC cell apoptosis caused by MPA.
Seven genes, including <i>RBM12, NDUFB6, ATP6V1A, RECK, SLC35E1, RFX3</i> (<i>Bonferroni-corrected P</i> < 0.05) and <i>ATP8A1</i> (suggestive <i>P</i> < 10<sup>-5</sup>), and one long non-coding RNA, <i>DLGAP4-AS1</i> (<i>Bonferroni-corrected P</i> < 0.05), were associated with endometrial cancer.
We found that expression of DLX7, a splicing isoform of DLX4, did not show any significant difference in expression between endometrial cancer and endometrium.
The association of decreased FAT4 expression with advanced signature (lymph node metastasis, lymphovascular invasion and muscular infiltration) in EC patients was also confirmed by our own dataset.
Additionally, there are active regulatory effects in dysfunction modules, thus genes such as ANO2 and EMP3 would be identified as key genes, which are associated with the development of EC.